Literature DB >> 24032460

Alternative polyadenylation and miR-34 family members regulate tau expression.

John R Dickson1, Carla Kruse, Daniel R Montagna, Bente Finsen, Michael S Wolfe.   

Abstract

Tau pathologically aggregates in Alzheimer's disease, and evidence suggests that reducing tau expression may be safe and beneficial for the prevention or treatment of this disease. We sought to examine the role of the 3'-untranslated region (3'-UTR) of human tau mRNA in regulating tau expression. Tau expresses two 3'-UTR isoforms, long and short, as a result of alternative polyadenylation. Using luciferase reporter constructs, we found that expression from these isoforms is differentially controlled in human neuroblastoma cell lines M17D and SH-SY5Y. Several microRNAs were computationally identified as candidates that might bind the long, but not short, tau 3'-UTR isoform. A hit from a screen of candidates, miR-34a, was subsequently shown to repress the expression of endogenous tau protein in M17D cells. Conversely, inhibition of endogenously expressed miR-34 family members leads to increased endogenous tau expression. In addition, through an unbiased screen of fragments of the human tau 3'-UTR using a luciferase reporter assay, we identified several other regions in the long tau 3'-UTR isoform that contain regulatory cis-elements. Improved understanding of the regulation of tau expression by its 3'-UTR may ultimately lead to the development of novel therapeutic strategies for the treatment of Alzheimer's disease and other tauopathies. mRNA 3'-untranslated regions (3'-UTR) often regulate transcript stability or translation. Despite the centrality of the tau protein in Alzheimer's and other neurodegenerative diseases, the human tau 3'-UTR has been little studied. This report identifies regions of the tau 3'-UTR that influence expression and shows that microRNA (miR)-34a targets this 3'-UTR to lower expression, which is considered an important therapeutic goal.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  3′-untranslated region; Alzheimer's disease; MAPT; gene regulation; neurodegenerative disease

Mesh:

Substances:

Year:  2013        PMID: 24032460      PMCID: PMC3859707          DOI: 10.1111/jnc.12437

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  45 in total

1.  Embryonic lethal abnormal vision-like RNA-binding proteins regulate neurite outgrowth and tau expression in PC12 cells.

Authors:  G E Aranda-Abreu; L Behar; S Chung; H Furneaux; I Ginzburg
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

2.  Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets.

Authors:  Massimiliano Agostini; Paola Tucci; Richard Killick; Eleonora Candi; Berna S Sayan; Pia Rivetti di Val Cervo; Pierluigi Nicotera; Frank McKeon; Richard A Knight; Tak W Mak; Gerry Melino
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

3.  Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells.

Authors:  M Encinas; M Iglesias; Y Liu; H Wang; A Muhaisen; V Ceña; C Gallego; J X Comella
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

4.  A genomic sequence analysis of the mouse and human microtubule-associated protein tau.

Authors:  P Poorkaj; A Kas; I D'Souza; Y Zhou; Q Pham; M Stone; M V Olson; G D Schellenberg
Journal:  Mamm Genome       Date:  2001-09       Impact factor: 2.957

Review 5.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

6.  Identification of 3'UTR region implicated in tau mRNA stabilization in neuronal cells.

Authors:  S Aronov; R Marx; I Ginzburg
Journal:  J Mol Neurosci       Date:  1999-04       Impact factor: 3.444

Review 7.  microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review).

Authors:  May Y W Wong; Yan Yu; William R Walsh; Jia-Lin Yang
Journal:  Int J Oncol       Date:  2011-03-10       Impact factor: 5.650

8.  Tau protein function in living cells.

Authors:  D G Drubin; M W Kirschner
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

9.  MicroRNA expression in Alzheimer blood mononuclear cells.

Authors:  Hyman M Schipper; Olivier C Maes; Howard M Chertkow; Eugenia Wang
Journal:  Gene Regul Syst Bio       Date:  2007-12-20

10.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

View more
  53 in total

Review 1.  Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?

Authors:  Juan F Codocedo; Juvenal A Ríos; Juan A Godoy; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

Review 2.  Alternative polyadenylation in the nervous system: to what lengths will 3' UTR extensions take us?

Authors:  Pedro Miura; Piero Sanfilippo; Sol Shenker; Eric C Lai
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

3.  RNA protein granules modulate tau isoform expression and induce neuronal sprouting.

Authors:  Katharina Moschner; Frederik Sündermann; Heiko Meyer; Abel Pereira da Graca; Neele Appel; Achim Paululat; Lidia Bakota; Roland Brandt
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

Review 4.  MicroRNAs in glaucoma and neurodegenerative diseases.

Authors:  Milena Molasy; Anna Walczak; Jerzy Szaflik; Jacek P Szaflik; Ireneusz Majsterek
Journal:  J Hum Genet       Date:  2016-07-14       Impact factor: 3.172

5.  Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma.

Authors:  Jessica L Childs-Disney; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2015-12-07       Impact factor: 5.100

6.  Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.

Authors:  Neven A Hagag; Yasser B M Ali; Ahmed A Elsharawy; Roba M Talaat
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 7.  Noncoding RNAs in Alzheimer's disease.

Authors:  M Laura Idda; Rachel Munk; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-01-12       Impact factor: 9.957

Review 8.  Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology.

Authors:  Jianping Guo; Ji Cheng; Brian J North; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-07-08       Impact factor: 10.680

Review 9.  A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease.

Authors:  P Hemachandra Reddy; Sahil Tonk; Subodh Kumar; Murali Vijayan; Ramesh Kandimalla; Chandra Sekhar Kuruva; Arubala P Reddy
Journal:  Biochem Biophys Res Commun       Date:  2016-08-12       Impact factor: 3.575

Review 10.  Alzheimer's disease: presence and role of microRNAs.

Authors:  Manasa Basavaraju; Alexandre de Lencastre
Journal:  Biomol Concepts       Date:  2016-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.